ClinicalTrials.gg
Status unknownNCT03792958Updated Nov 14, 2022

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

A Phase 1 interventional study of CM082 in Advanced Malignant Solid Tumors, sponsored by AnewPharma. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by AnewPharma (part of Betta Pharmaceuticals Co., Ltd.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors

Read the detailed description

This is a single-center、open-label and non-controlled Phase 1 study which will be conducted in two parts: part A is the dose-escalation phase; part B is dose-expansion phase. The dose-escalation phase is guided by pharmacokinetics (PK) and safety, according to the standard 3+3 dose-escalation schema. CM082 tablets are taken orally with a starting dose of 200 mg and a subsequent dose of 400, 600 and 800 mg. The way of administration is as follows: QD or BID. The primary objective of this study is to determine the maximum tolerable dose (MTD)、characteristics of dose-limited toxicity (DLT) and pharmacokinetics (PK). Secondary objectives include safety、tolerability and preliminary efficacy

02

Conditions studied

  • Advanced Malignant Solid Tumors
03

In context

Lead sponsor

AnewPharma is the lead sponsor of 14 studies on the registry; none are open to participants now.

First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age:≥18 years.
  • generally ranges from 18-28 (BMI=Weight (Kg)/Height (m)2)
  • Patients with advanced malignant solid tumors confirmed by histological or cytological examination.
  • According to Recist1.1 criteria, patients have measurable or assessable tumors, and patients with advanced malignant solid tumors who have failed to respond to previous standard treatment regimens, are unable to tolerate previous treatment regimens or lack effective treatment regimens.
  • Organ function level must meet the following requirements (7 days before treatment):

    • Bone marrow: (ANC)≥1.5\^109/L, (PLT)≥100\^109/L, (HB)≥9g/dL (no blood transfusion or component blood received within 14 days before detection).
    • Liver: Serum (TBIL) ≤1.5 * (ULN) , (AST) and alanine aminotransferase (ALT) ≤ 2.5 * ULN (If the patient's liver , AST and ALT are allowed to be ≤ 5 * ULN) ).
    • Serum creatinine≤1.5 * ULN and endogenous rate≥50mL/min. According to Cockcroft-Gault formula, Please refer to attachment 7 for details.
    • (INR) and activated partial thromboplastin time (APTT)≤1.5 * ULN (This provision applies only to patients who do not receive anticoagulant treatment; for patients receiving anticoagulant treatment, anticoagulants should be used within the treatment requirements).
    • Urine protein (UP)≤1+. If UP>1+, 24-hour UP should be collected for determination, and the total amount of UP should be ≤1g.
    • FT3、FT4 and thyroid-stimulating hormone (TSH) are normal or abnormal without clinical significance(Except for advanced thyroid cancer).
  • No immunodeficiency.
  • The damage causes by other treatments is restored to 1 grade ( version 4.03), except for hair loss and pigmentation; If the nutritional status is stable, the long-term toxicity that cannot be recovered is allowed to exist by the investigator'judgement.
  • Expected survival time≥ 3 months.
  • Eastern Cooperative Group () Performance Status score of ≤1.
  • The results of serum pregnancy test for women of childbearing age should be negative within 7 days before treatment.
  • Men who are fertile or women who are likely to become pregnant must use highly effective methods (e.g., oral contraceptives, intrauterine contraceptives, sex control or barrier contraceptives combined with spermicides ) throughout the trial and continue to use contraception for 12 months after the end of treatment.
  • Patients can voluntarily sign written .

Exclusion criteria

Exclusion Criteria:

-Within 4 weeks before the first use of the study drug, the patient received anti- tumor drug therapy such as chemotherapy, targeted therapy, radiotherapy, biological therapy or endocrine therapy, except for the following: Nitrous urea or mitomycin C were used within 6 weeks before the first use of the study drug; Oral fluorouracil and small molecular targeted drugs were used within 2 weeks before the first use of the study drug or within 5 half-lives (whichever is the longer); Chinese medicine with anti-cancer indications was used within 1 week before the first use of the study drug.

  • Surgical treatment (except ) was performed within 4 weeks before the first use of study drug.
  • Patients who have participated in or are participating in any other drug/therapy clinical trial (including but not limited to the anti-tumor clinical trial) within 4 weeks before treatment, counting from the time of last administration of the last clinical trial.
  • Patients who received hematopoietic stimulating factors (e.g., granulocyte colony stimulating factor (G-CSF), erythropoietin, etc.) within one week before treatment.
  • Pleural or ascites with clinical symptoms and requiring symptomatic treatment.
  • Patients with active pulmonary disease, interstitial pneumonia or pulmonary fibrosis.
  • Having any uncontrollable clinical problems or associated risk factors, including but not limited to:

    • Poorly controlled hypertension (blood pressure persistently greater than 150/90 mmHg).
    • (LVEF)≤50%.
    • The of heart rate correction (QTc) > 450 msec (males) or 460 msec (females) ( Bazett's correction (QTcB)=QT/(RR\^0.5)).
    • Patients have a history of arrhythmia or current evidence of arrhythmia, but control of atrial fibrillation for more than 30 days before administration does not affect inclusion.
    • Patients implanted with cardiac defibrillator.
    • Poorly controlled diabetes [(fasting blood glucose should not be greater than 8.9 mmol/L after drug control) refer to version 4.03-grade 1 of hyperglycemia].
    • Heart disease (Class III/IV congestive heart failure or cardiac block defined by the ).
    • Decompensated cirrhosis.
    • The following conditions occur within 6 months before treatment:

      • Deep venous thrombosis or pulmonary embolism.
      • Myocardial infarction.
      • Severe or unstable arrhythmia or angina pectoris.
      • Percutaneous Coronary Intervention, Acute Coronary Syndrome, Coronary Artery Bypass Transplantation.
      • Cerebrovascular accident, or resting limping of lower limbs.
  • Patients have not yet fully recovered from previous operations.
  • Patients who have taken strong inhibitors and inducers of hepatic metabolic enzymes within 2 weeks before treatment.
  • Patients also take drugs that are at risk of prolonging QTc and/or Tdp.
  • Patients with a history of allergy to CM082 similar drugs (e.g., sunitinib, sorafenib, pazopanib, etc.).
  • Pregnant or lactating women.
  • Women/men with fertility who refuse to use during the trial.
  • Any uncontrollable clinical problem (such as serious mental, neurological, cardiovascular, respiratory and other system diseases) or active infection that significantly affects clinical trials.
  • The patient has clinical symptoms or uncontrolled central nervous system or meningeal metastasis, which is judged by the investigator to be unsuitable for admission;
  • Patients with active upper gastrointestinal ulcer or other diseases known to affect drug absorption, distribution, metabolism or clearance.
  • Patients with obvious abnormal gastrointestinal function such as vomiting、 diarrhea, etc..
  • Positive results of or Treponema pallidum antibodies (Acceptance of Treponema pallidum antibody titer test results in a Class III Grade I hospital including research centers).
  • Patients with active or C:

    • HBsAg or HBcAb are positive, and hepatitis B virus (HBV) DNA is detected (the results are higher than the of the research center).
    • virus (HCV) antibody test results are positive, and HCV RNA is detected (the results are higher than the upper limit of the normal range of the research center).
  • Patients who have progressed after using a receptor tyrosine kinase inhibitor that targets VEGFR.
  • Investigators consider that it is not appropriate for subjects to participate in this study from the perspective of clinical treatment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    CM082

    CM082 tablet

    Drug: CM082

Interventions

  • DrugCM082

    CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)

    Also known as: X-82

06

What researchers measure

Primary outcomes

  1. Maximum tolerable dose (MTD) or dose to absorb saturation

    Time frame: From the first dose to the 28th day of administration

  2. Dose-Limiting Toxicity

    Characteristics of dose-limiting toxicity (DLT), evaluation criteria: National Cancer Institute (NCI) CTC classification (version 4.03)

    Time frame: From the first dose to the 28th day of administration

  3. Pharmacokinetic parameters

    Peak concentration

    Time frame: From the first dose to the 28th day of administration

  4. Pharmacokinetic parameters

    Area under the time curve of blood concentration from 0 h to the last time of blood collection

    Time frame: From the first dose to the 28th day of administration

  5. Pharmacokinetic parameters

    0 to Infinite Area under Blood Drug Concentration Curve

    Time frame: From the first dose to the 28th day of administration

  6. Pharmacokinetic parameters

    Peak time

    Time frame: From the first dose to the 28th day of administration

  7. Pharmacokinetic parameters

    Apparent terminal elimination half-life

    Time frame: From the first dose to the 28th day of administration

  8. Pharmacokinetic parameters

    Terminal elimination rate constant

    Time frame: From the first dose to the 28th day of administration

Secondary outcomes

  1. Objective response rate

    Time frame: 12 months

  2. Disease control rate

    Time frame: 12 months

  3. Progression-free survival

    Time frame: 12 months

  4. Overall survival

    Time frame: 36 months

07

Study locations

1 site
  • Shanghai East Hospital
    Shanghai, Shanghai 200120, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2019 (actual). Primary completion is estimated for Jun 2023, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2018
First posted
Jan 4, 2019
StartActual
Feb 26, 2019
Primary completionEst.
Jun 2023
CompletionEst.
Jun 2023
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03792958
Lead sponsor
AnewPharma
Collaborators
Shanghai East Hospital
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Feb 26, 2019
Primary completion
Jun 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Nov 14, 2022

Study contacts

Jin Li, M.D
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion